[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586518":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":19,"responsibleParty":32,"collaborators":19,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":19,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":19,"overallStatus":54,"whyStopped":19,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":19},{"fullName":5,"class":6},"University of Cologne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pembrolizumab","EXPERIMENTAL","All patients will receive 6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by 20Gy radiotherapy",[13],"Drug: Pembrolizumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Dennis Eichenauer, Dr.","University Hospital of Cologne","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Michael Fuchs","CONTACT","+49221478","88160","michael.fuchs@uk-koeln.de",{"type":24,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Dr. Dennis Eichenauer","Dr.","100586518","phase-2-phase-ii-trial-of-anti-pd-1-antibody-treatment-and-radiotherapy-in-early-stage-favorable-classic-hodgkin-lymphoma-100586518",false,"NCT06916416","Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma","PREFer","Inclusion Criteria:\n\n* Histologically proven first diagnosis of cHL\n* Stage I-II without risk factors\n\n  * Large mediastinal mass\n  * Extranodal involvement\n  * Elevated erythrocyte sedimentation rate (ESR)\n  * Involvement of ≥ 3 nodal areas\n\nExclusion Criteria:\n\n* Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,\n* Prior cHL-directed treatment\n* Prior chemotherapy, RT or allogeneic stem cell\u002Fsolid organ transplant\n* Prior or concurrent disease precluding protocol treatment (for details see section 4.2)\n* Pregnancy or breastfeeding\n* Non-compliance","ALL","18 Years","75 Years",{"count":46,"type":47},50,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.",[53],"Classical Hodgkin Lymphoma","NOT_YET_RECRUITING","2025-03-31",{"date":57,"type":58},"2025-04-08","ACTUAL",{"date":60,"type":47},"2025-06",{"date":62,"type":47},"2028-06",{"name":5,"class":6}]